嘉必优生物技术（武汉）股份有限公司 远期外汇管理制度 第一章 总则 第一条 为进一步规范嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）远期外汇交易业务，防范国际贸易业务中的汇率风险，根据《中华人民共 和国公司法》、《中华人民共和国证券法》、《结汇、售汇及付汇管理规定》、《上市 公司信息披露管理办法》等国家相关法律法规及《公司章程》的有关规定，结合 公司实际经营情况，特制定本制度。 第二条 本制度所称远期外汇交易业务是指为满足正常生产经营需要，利用 银行金融产品等对外汇资产进行保值，锁定或减少外汇相关财务成本，规避和防 范汇率风险的业务，包括远期结售汇业务、人民币外汇掉期业务以及其他外汇衍 生品业务等。 第三条 本制度适用于公司及其下属全资子公司，控股子公司。 第二章 远期外汇交易业务原则 第四条 公司进行远期外汇交易业务遵循合法、审慎、安全和有效的原则， 严格控制远期外汇交易业务的交易种类及规模，不进行单纯以盈利为目的的外汇 交易，所有外汇交易行为均以正常经营业务为基础。 第五条 公司进行远期外汇交易业务只允许与经国家相关金融监管机构批准、 具有远期外汇交易业务经营资格的金融机构进行交易，不得与前述 ...

嘉必优生物技术（武汉）股份有限公司 独立董事关于第三届董事会第十五次会议相关事项的独立意见 嘉必优生物技术(武汉)股份有限公司 2023 年 8 月 25 日 根据《中华人民共和国公司法》、《上市公司独立董事规则》以及《公司章 程》等相关规定，我们作为嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）的独立董事，本着认真负责的工作态度，基于独立判断的立场，对公司第 三届董事会第十五次会议审议的相关事项进行了审核，发表如下独立意见： 一、关于公司 2023 年半年度募集资金存放与使用情况专项报告的独立意见 我们认为，公司第三届董事会第八次会议审议的《关于<公司 2023 年半年度 募集资金存放与使用情况的专项报告>的议案》，公司 2023 年半年度募集资金存 放与使用情况符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》、《上海证券交易所科创板股票上市规则》等法律法规、规范性文 件的规定，符合公司《募集资金使用与管理制度》的规定，对募集资金进行了专 户存储和专项使用，并及时履行了相关信息披露义务，募集资金具体使用情况与 公司已披露情况一致，不存在变相改变募集资金用途和损害股东利益 ...

证券代码：688089 证券简称：嘉必优 公告编号：2023-039 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开第三届董事会第十五次会议和第三届监事会第十五次会议，审议通过 了《关于调整 2022 年限制性股票激励计划相关事项的议案》，同意根据公司《2022 年限制性股票激励计划（草案）》的有关规定，对 2022 年限制性股票激励计划相 关事项进行调整。具体调整情况如下： 一、公司 2022 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2022 年 1 月 17 日，公司召开第三届董事会第二次会议，审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股东大会授权 董事会办理股权激励相关事宜的议案》等相关议案。公司独立董事就激励计划相 关议案发表了独立意见。 同日，公司召开第三届监事会第二次会议，审议通过了《 ...

嘉必优生物技术（武汉）股份有限公司 第三条 公司对外担保行为应当遵循合法、审慎、互利、安全的原则，严格 控制担保风险。 第四条 公司股东大会和董事会是对外担保的决策机构，公司一切对外担保 行为，须按程序经公司股东大会或董事会批准。未经公司股东大会或董事会的批 准，公司不得对外提供担保。 第二章 对外担保的审批权限 第五条 公司下列对外担保事项，须经董事会审议通过后，提交股东大会审 议批准： （一）单笔担保额超过公司最近一期经审计净资产 10％的担保； 1 对外担保管理制度 第一章 总 则 第一条 为有效控制嘉必优生物技术（武汉）股份有限公司（以下简称"公司"） 对外担保风险，保护投资者合法权益，保证公司科学、安全与高效地做出决策， 明确公司股东大会、董事会等组织机构在公司对外担保决策方面的职责，控制财 务和经营风险，依据《中华人民共和国公司法》《中华人民共和国证券法》、中 国证券监督管理委员会（以下简称"中国证监会"）《上市公司监管指引第8号—— 上市公司资金往来、对外担保的监管要求》《上海证券交易所科创板股票上市规 则》（以下简称"《上市规则》"）等法律、法规、规章、规范性文件及《嘉必优 生物技术（武汉）股 ...

嘉必优生物技术（武汉）股份有限公司 内部控制制度 第一章 总则 第一条 为了加强和规范嘉必优生物技术（武汉）股份有限公司（以下简称 "公司"）内部控制，促进公司规范运作和健康发展，保护投资者合法权益， 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《企业内部控 制基本规范》、《上海证券交易所股票上市规则》、《上海证券交易所科创板 上市公司自律监管指引第1号—规范运作》等法律法规和规范性文件的规定，结 合《嘉必优生物技术（武汉）股份有限公司章程》（以下简称"公司章程"） 及公司的实际情况，制定本制度。 第二条 内部控制是指由公司董事会、监事会、经营管理层和全体员工实施 的、为实现内部控制目标而提供合理保证的过程。 第三条 公司内部控制的目标 （三）保障公司资产安全，提升管理水平，增进对公司股东的回报； （四）确保财务报告及相关信息披露真实、准确、完整、及时和公平。 第二章 组织机构与职责 第四条 公司建立与实施内部控制，应当遵循下列原则： （一）全面性原则。内部控制应当贯穿决策、执行和监督全过程，覆盖公 司各种业务和事项。 （三）制衡性原则。内部控制应当在治理结构、机构设置及权责分配、业 务流程等方面 ...

证券代码：688089 证券简称：嘉必优 公告编号：2023-032 嘉必优生物技术（武汉）股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 5 日（星期一）上午 10：00-11：00 （一）会议召开时间：2023 年 6 月 5 日（星期一）上午 10：00-11：00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络文字互动 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.s seinfo.com） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 5 月 29 日（星期一）至 2023 年 6 月 2 日（星期五） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@cabio.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）已于 2023 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 87,762,301.30, representing a year-on-year increase of 16.18%[5]. - Net profit attributable to shareholders decreased by 38.40% year-on-year, amounting to CNY 14,307,104.28[5][9]. - The net profit after deducting non-recurring gains and losses fell by 47.96%, totaling CNY 7,302,325.16[5][9]. - The net profit for Q1 2023 was CNY 13,529,876.56, a decrease of 38.5% compared to CNY 22,013,486.90 in Q1 2022[20]. - Operating profit for Q1 2023 was CNY 11,084,400.27, down 43.4% from CNY 19,512,167.40 in the same period last year[20]. - The total comprehensive income for Q1 2023 was CNY 13,529,876.56, compared to CNY 21,533,439.04 in Q1 2022[21]. - Basic and diluted earnings per share were both CNY 0.12, reflecting a decrease of 37.25% year-on-year[6][9]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.12, down from CNY 0.19 in the same quarter last year[21]. Cash Flow - The net cash flow from operating activities was negative at CNY -5,286,511.48, a decline of 108.22% compared to the previous year[6][9]. - Cash flow from operating activities turned negative at CNY -5,286,511.48, compared to a positive CNY 64,335,059.13 in Q1 2022[24]. - The company reported a net cash outflow from investing activities of CNY -108,285,178.74, an improvement from CNY -187,471,146.88 in Q1 2022[24]. - The total cash inflow from investment activities was CNY 161,357,266.04, a decrease of 50.0% compared to CNY 323,026,382.45 in Q1 2022[34]. - The net cash flow from investment activities was -CNY 111,127,175.72, an improvement from -CNY 189,490,113.90 in Q1 2022[34]. - Cash and cash equivalents at the end of Q1 2023 were CNY 361,033,982.93, down from CNY 529,569,351.18 at the end of Q1 2022[34]. - The cash outflow for purchasing goods and services increased to CNY 76,920,055.38, up 105.0% from CNY 37,475,015.22 in Q1 2022[32]. - The company did not report any cash inflow from financing activities in Q1 2023[34]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,592,109,549.99, a decrease of 1.16% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to RMB 1,592,109,549.99, a slight decrease from RMB 1,610,828,359.79 at the end of 2022[15]. - Total liabilities decreased to RMB 150,553,704.96 from RMB 185,767,562.26, indicating a reduction of 19%[16]. - The company's total liabilities decreased to CNY 199,235,766.86 in Q1 2023 from CNY 234,618,597.19 in Q4 2022, a reduction of approximately 15.1%[28]. - Shareholders' equity increased to RMB 1,441,555,845.03 from RMB 1,425,060,797.53, showing a growth of 1.2%[16]. - The company's total equity increased to CNY 1,461,999,276.93 in Q1 2023 from CNY 1,444,628,761.79 in Q4 2022, showing a growth of 1.2%[28]. Research and Development - Research and development expenses totaled CNY 7,517,071.87, which is 8.57% of operating revenue, an increase of 0.46 percentage points year-on-year[6]. - Research and development expenses increased to CNY 7,517,071.87, up 22.8% from CNY 6,121,712.21 in the previous year[20]. - Research and development expenses increased to CNY 6,578,632.54 in Q1 2023, up from CNY 5,491,702.14 in Q1 2022, indicating a growth of 19.8%[30]. Inventory and Accounts Payable - Inventory levels rose to RMB 115,581,174.69, up from RMB 81,490,915.63, marking an increase of 42%[14]. - The company reported a decrease in accounts payable to RMB 86,224,694.99 from RMB 107,335,303.41, a decline of 19.7%[15]. - The company's inventory increased to CNY 110,586,346.86 in Q1 2023 from CNY 78,443,729.20 in Q1 2022, reflecting a growth of 41.0%[27]. Market Strategy - The company is focused on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[13].

Financial Performance - The company's operating revenue for 2022 was CNY 433.42 million, an increase of 23.44% compared to CNY 351.11 million in 2021[22]. - Net profit attributable to shareholders decreased by 49.94% to CNY 64.37 million from CNY 128.58 million in 2021[22]. - The net cash flow from operating activities increased by 70.78% to CNY 176.40 million compared to CNY 103.29 million in 2021[22]. - Basic earnings per share dropped by 49.53% to CNY 0.54 from CNY 1.07 in 2021[23]. - The total assets of the company increased by 11.21% to CNY 1.61 billion from CNY 1.45 billion in 2021[22]. - The company reported a significant increase in sales expenses due to intensified market expansion efforts for new products and services[24]. - The gross margin for human nutrition products was 46.47%, a decrease of 3.71 percentage points compared to the previous year[103]. - The company’s ARA product revenue was CNY 255,584,220.82, with a gross margin of 49.34%, down by 0.48 percentage points[104]. - Domestic market revenue growth was limited to 2.56% due to inventory destocking in the dairy industry[105]. - The international market revenue increased by 36.42%, benefiting from higher market share with major clients like Nestlé[105]. Research and Development - The company is focused on expanding its market presence and developing new products and technologies[12]. - Research and development expenses accounted for 7.45% of operating revenue, down from 8.81% in 2021[23]. - The company has developed over 15 new products using synthetic biology technology and established an industrial strain library in 2022[42]. - The company has formed strategic partnerships with multiple universities and research institutions to enhance its R&D ecosystem[41]. - The company achieved a total R&D investment of ¥32,296,449.13, representing a 4.36% increase from the previous year's ¥30,947,095.88[78]. - The company has developed a series of products using lipid nano co-delivery technology, showing good moisturizing and repair effects[70]. - The company has developed over 31 enzymes related to the synthesis pathways of HMOs and polyunsaturated fatty acids, achieving structural analysis or prediction[67]. - The company has established a comprehensive technology system for the efficient construction of industrial strains, achieving international advanced levels in strain rearrangement technology[82]. Market Expansion and Strategy - The company plans to enhance its product line by accelerating the development of new products, including HMOs and α-arbutin[143]. - The company aims to maintain its leadership position in the domestic ARA market while increasing its international market share[143]. - The company is actively developing new products and expanding into animal nutrition and personal care sectors, leveraging its expertise in human nutrition[93]. - The company aims to become a leading brand in the global ARA market and a major supplier in the algae oil DHA market, focusing on international development strategies in Australia and Southeast Asia[144]. - The company plans to explore international markets following the expiration of DSM's ARA patents in June 2023, targeting Europe, North America, and Southeast Asia for expansion[147]. Corporate Governance and Investor Relations - The company emphasizes that forward-looking statements do not constitute a commitment to investors, highlighting investment risks[6]. - The company is committed to ensuring the accuracy and completeness of its financial reports[5]. - The company has implemented a stock incentive plan to motivate and retain key personnel[164]. - The company plans to enhance its capital brand and value communication with investors in the future[161]. - The company has not faced significant issues regarding independence from its controlling shareholders[161]. - The company will maintain strict information disclosure obligations and improve investor relations management to ensure transparency and trust[160]. Operational Risks and Compliance - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company has no non-operational fund occupation by controlling shareholders or related parties[7]. - The company has no violations of decision-making procedures regarding external guarantees[8]. - The company faces risks related to food safety and product quality control, which are critical in the infant formula sector, and any failure in these areas could lead to significant negative impacts[93]. - The company is exposed to risks from fluctuations in energy and raw material prices, which could affect production costs and profitability[94]. Awards and Recognition - The company has received multiple awards, including the National Science and Technology Progress Award, and has participated in the formulation of national standards[60]. - The company has received multiple awards for its technological advancements, including a first prize for technological progress from the China Light Industry Federation[70]. Future Outlook - Future guidance indicates a cautious outlook, with expectations of gradual recovery in user engagement metrics[167]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of $50 million[168]. - The company is exploring partnerships with key industry players to enhance distribution channels and drive growth[168].

关于上海证券交易所《关于嘉必优生物技术 （武汉）股份有限公司 2022 年业绩快报 更正暨资产减值风险、补充确认关联交易等 有关事项的问询函》回复的核查意见 大信备字[2023]第 2-00012 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants LLP. Room2206 22/F,Xueyuan International Tower No.1 ZhichunRoad,Haidian Dist. Beijing,China,100083 电话 Telephone： +86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 关于上海证券交易所《关于嘉必优生物技术（武汉）股份有限 公司 2022 年业绩快报更正暨资产减值风险、补充确认关联交 易等有关事项的问询函》回复的核查意见 大信备 ...

编号：2022-06 投资者关系 活动类别 特定对象调研 分析师会议 □媒体采访 □业绩说明会 □新闻发布会 路演活动 现场参观 其他 电话会议 证券代码： 688089 证券简称： 嘉必优 嘉必优生物技术（武汉）股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|-------|---------------------------|--------| | | | | | | 参与单位名称及 | 序号 | 公司 | 姓名 | | | | 4 月 30 日 10:00-11:00 | | | 人员姓名 | 1 | 开源证券 | 方勇 | | | 2 | 浙商 | 韩佳伟 | | | 3 | 长城财富 | 缴文超 | | | 4 | 财通基金 | 姜春曦 | | | 5 | 德邦 | 刘敏 | | | 6 | 恒越 | 陈凯茜 | | | 7 | 华泰柏瑞 | 王欣然 | | | 8 | 中邮 | 綦征 | | | 9 | 招银理财 | 杨鈜毅 | | | 10 | 太平 | 肖婵 | | | 11 | 太平 | 项韬 | | | 12 | ...